Ewing Sarcoma with ERG Gene Rearrangements: A Molecular Study Focusing on the Prevalence of FUS-ERG and Common Pitfalls in Detecting EWSR1-ERG Fusions by FISH
Overview
Oncology
Affiliations
The genetics of Ewing sarcoma (ES) are characterized by a canonical fusion involving EWSR1 gene and a member of the ETS family of transcription factors, such as FLI1 and ERG. In fact, ERG gene rearrangements represent the second most common molecular alteration, with EWSR1-ERG being identified in 5-10% of cases, while only a handful of reports document a FUS-ERG fusion. In this study, we focus on ES with ERG gene abnormalities, specifically to investigate the prevalence and clinicopathologic features of FUS-ERG fusions in a large cohort of small blue round cell tumors (SBRCTs) and compare to the eight reported FUS-positive ES. Among the 85 SBRCTs tested, seven (8.2%) cases harbored FUS gene rearrangements; six fused to ERG and one with FEV. During this investigation we came across a number of ERG-rearranged ES lacking both EWSR1 and FUS abnormalities by FISH. In one case, RNA sequencing identified an EWSR1-ERG transcript despite the negative EWSR1 rearrangements by FISH. Additional 3-color FISH fusion assay demonstrated the fusion of EWSR1 and ERG signals in all four cases negative for break-apart EWSR1 FISH. These results emphasize a potential pitfall of relying on EWSR1 FISH assay alone for diagnosis of ES. In cases with classic morphology and/or strong CD99 and ERG immunoreactivity, additional molecular testing should be applied, such as ERG FISH or RT-PCR/next generation sequencing, for a more definitive diagnosis. Although our study group is small, there were no differences noted between the clinical, morphologic features and immunoprofile of the different subsets of ERG-rearranged SBRCTs.
Case report: Pulmonary Ewing sarcoma disguised as non-small cell lung cancer.
Carter M, Benegiamo-Chilla A, Kloker L, Paulsen N, Potkrajcic V, Paulsen F Front Oncol. 2024; 14:1449119.
PMID: 39575427 PMC: 11578818. DOI: 10.3389/fonc.2024.1449119.
FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
Cao Z, Yang Y, Liu S, Sun L, Liu Y, Luo Y J Gastroenterol. 2024; 60(2):235-246.
PMID: 39537893 DOI: 10.1007/s00535-024-02175-y.
Malik S, Madan N, Agrawal M, Yadav R, Barwad A Autops Case Rep. 2024; 14:e2024499.
PMID: 39021466 PMC: 11253908. DOI: 10.4322/acr.2024.499.
Zerella J, Homan C, Arts P, Lin X, Spinelli S, Venugopal P Blood. 2024; 144(17):1765-1780.
PMID: 38991192 PMC: 11530364. DOI: 10.1182/blood.2024024607.
Zago Baltazar R, Claerhout S, Vander Borght S, Spans L, Sciot R, Schoffski P J Pathol Clin Res. 2024; 10(3):e12376.
PMID: 38738521 PMC: 11089496. DOI: 10.1002/2056-4538.12376.